BioCorRx Acquires Intellectual Property for Drug Delivery

Rhea-AI Summary

BioCorRx Inc. (OTCQB: BICX) announced the acquisition of a patent application from Calista Therapeutics covering a solid implant formulation for drug delivery. This patent, application number 17/465,748, may enhance current naltrexone formulations and is expected to add value to BioCorRx's existing intellectual property portfolio. CEO Lourdes Felix expressed excitement over the potential improvements in drug delivery systems, which could benefit the company’s treatment programs for substance abuse and related disorders.

Positive

• Acquisition of a patent application from Calista Therapeutics to enhance drug delivery systems.
• Potential improvements to current naltrexone formulations, which may lead to increased efficacy.
• Expansion of BioCorRx's intellectual property portfolio may attract future partnerships.

Negative

• None.

Patent Application Covers Solid Implant Formulation for Drug Delivery

ANAHEIM, CA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that the Company has acquired a patent application from Calista Therapeutics. The current application, 17/465,748, was filed with the U.S. Patent and Trademark Office (USPTO) covering solid implant formulation for drug delivery. This IP complements the Company’s current IP portfolio and may be used for improvements to current naltrexone formulations owned by the Company or licensed to third parties for use with other molecules where solid implant formulations are desired.

Lourdes Felix, CEO, CFO and Director of BioCorRx Inc., stated, “We are excited to add this new application to our portfolio which may improve certain aspects of solid implant drug delivery. We believe this IP adds value to our portfolio and we plan to explore its uses with our current formulations as well as with others in the implantable drug delivery space.”

About BioCorRx

BioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. Beat Addiction Recovery is a substance use disorder recovery program that typically includes BioCorRx's proprietary Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx® Weight Loss Program is also a medication assisted weight loss program that includes access to concierge on-demand wellness specialists: nutritionists, fitness experts and personal support from behavioral experts; please visit www.uncraverx.com for more information on UnCraveRx®. The Company also controls BioCorRx Pharmaceuticals, a clinical stage drug development subsidiary currently seeking FDA approval for BICX104, an implantable naltrexone pellet for treatment of alcohol and opioid use disorders. For more information on BICX and its subsidiary pipeline, please visit www.BioCorRx.com.

Safe Harbor Statement

The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown. risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com

Media Contact:
CMW Media
(858) 264-6600
biocorrx@cmwmedia.com

FAQ

What is the significance of the patent application acquired by BioCorRx (BICX)?

The acquired patent application covers a solid implant formulation for drug delivery, which may improve the efficacy of naltrexone treatments.

How might the new patent application impact BioCorRx's existing products?

The new patent could enhance current naltrexone formulations and may open up opportunities for the development of other implantable drug delivery systems.

When was the patent application for solid implant formulation filed?

The patent application, number 17/465,748, was filed with the U.S. Patent and Trademark Office.

Who is the CEO of BioCorRx Inc. and what did they say about the patent acquisition?

Lourdes Felix is the CEO, and she expressed excitement about the potential improvements in drug delivery systems from this acquisition.

What future applications does BioCorRx anticipate for the patent?

BioCorRx plans to explore the patent's uses both with its current formulations and other molecules in the implantable drug delivery space.